EP300 and cancer: Anti-cancer studies with SE-related CBP/p300 inhibitors have been conducted in hematologic malignant neoplasms such as multiple myeloma, acute myeloid leukemia, and non-Hodgkin’s lymphoma (Lasko et al., 2017), as well as in castration-resistant prostate cancer (Chen et al., 2022).